tbuckley/cabot-search huggingface dataset:
DNA synthesis in alveolar macrophages and other changes in lavaged cells following exposure of CBA/H mice to cigarette smoke.
Authors: S B Hornby, J P Kellington
Journal: Environmental Health Perspectives (1990)

Traditional methods to determine the proportion of cells in S-phase use radiolabeled precursors of DNA, such as 3H-thymidine, which become incorporated into DNA during its synthesis and are visualized either in tissue sections or in cell preparations by autoradiography. At the Harwell Laboratory the effects of inhaled alpha-emitting actinides on the pulmonary alveolar macrophage population of the rodent lung are being studied. For this research the use of an autoradiographic technique to determine the proportion of cells in S-phase is inappropriate, because of the possible presence of competing sources of radioactivity in the cells under investigation. Consequently, an alternative method has been developed. In this method, 5-bromodeoxyuridine (BrdU), an analogue of thymidine, is incorporated into cells undergoing DNA synthesis. Fluorescein-conjugated monoclonal antibodies, highly specific for BrdU substituted DNA, are available commercially and may be used as a probe for BrdU-labeled cells. This technique for identifying cells in S-phase has been described previously for the flow cytometric analysis of cell suspensions and for cells in tissue sections. An adaptation of this technique for use on cytocentrifuge preparations of cells recovered from mouse lung by bronchoalveolar lavage has been developed and its use is described. Some preliminary results of a short-term experiment with CBA/H mice to determine the effects of exposure to cigarette smoke on the DNA synthesis of alveolar macrophages are also included.
Khalid Naji
Authors: N. K Baban
Journal: BMJ (2009)

<h3>Abstract</h3> Many natural sounds have frequency spectra composed of integer multiples of a fundamental frequency. This property, known as harmonicity, plays an important role in auditory information processing. However, the extent to which harmonicity influences the processing of sound features beyond pitch is still unclear. This is interesting because harmonic sounds have lower information entropy than inharmonic sounds. According to predictive processing accounts of perception, this property could produce more salient neural responses due to the brain’s weighting of sensory signals according to their uncertainty. In the present study, we used electroencephalography to investigate brain responses to harmonic and inharmonic sounds commonly occurring in music: piano tones and hi-hat cymbal sounds. In a multi-feature oddball paradigm, we measured mismatch negativity (MMN) and P3a responses to timbre, intensity, and location deviants in listeners with and without congenital amusia—an impairment of pitch processing. As hypothesized, we observed larger amplitudes and earlier latencies (for both MMN and P3a) in harmonic compared to inharmonic sounds. These harmonicity effects were modulated by sound feature. Moreover, the difference in P3a latency between harmonic and inharmonic sounds was larger for controls than amusics. We propose an explanation of these results based on predictive coding and discuss the relationship between harmonicity, information entropy, and precision weighting of prediction errors.
HONEYCOMD ATROPHY*
Authors: LOUIS SAVATARD
Journal: British Journal of Dermatology (1943)

Journal Article HONEYCOMD ATROPHY Get access LOUIS SAVATARD LOUIS SAVATARD Manchester Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 55, Issue 11, 1 November 1943, Pages 259–266, https://doi.org/10.1111/j.1365-2133.1943.tb10717.x Published: 01 November 1943
Circulating interleukin-10 levels correlate with endotoxemia in chronic liver disease Department of Medicine, University Hospital Innsburck, Innsburck, Austria
Journal: Hepatology (1995)

Increased plasma levels of von Willebrand factor (VWF) have been reported in acute myocardial infarction (AMI). Recently, we showed reduced activity of a VWF-cleaving protease (ADAMTS13) in AMI patients. However, there is no information as to whether ADAMTS13 affects the pathogenesis of unstable angina (UA). Thus, the purpose of this study was to examine changes in plasma VWF and ADAMTS13 levels in UA patients.Plasma VWF and ADAMTS13 levels (mU/ml) were measured in 45 patients with UA, 55 with stable exertional angina (SEA) and 47 with chest pain syndrome (CPS) at the time of coronary angiography. Levels were also measured in 15 UA patients after 6 months of follow-up.VWF antigen levels (mU/ml) increased significantly in UA patients compared with SEA or CPS (2129.3 ± 739.5, 1571.8 ± 494.2 and 1569.5 ± 487.0, respectively; P < 0.0001 in UA vs. SEA or CPS). ADAMTS13 antigen levels (mU/ml) were significantly lower in UA patients than SEA or CPS (737.3 ± 149.5, 875.3 ± 229.0 and 867.7 ± 195.5, respectively; P < 0.01 in UA vs. SEA or CPS). Furthermore, there was a significant inverse correlation between VWF and ADAMTS13 antigen levels (r = -0.302, P = 0.0002). The antigen levels at 6 months of follow-up were not different compared to the acute phase in the 15 UA patients that had repeated blood sampling.These findings suggest that there is prolonged thrombogenicity in UA patients represented as an imbalance between VWF and ADAMTS13 activity.
Air Raid Precautions
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Basal-Cell Carcinoma
Authors: Adam I. Rubin, Elbert H. Chen, Désirée Ratner
Journal: New England Journal of Medicine (2005)

Basal-cell carcinoma is the most common malignant tumor, and its incidence is increasing. This review explains the treatment options, including four surgical approaches, topical therapy, photodynamic therapy, and radiation. Recent research on the pathogenesis is also summarized.
Abstract 477: Targeted deep sequencing contributes to guiding personalized targeted therapy in advanced biliary tract cancer
Authors: Feiling Feng, Qingbao Cheng, Dadong Zhang, Bin Li, Hao Qin, Chang Xu, Miao Han, Yong Yu, Zhizhen Li, Jing-Yu Li, Zhiquan Qiu, Lei Xiong, Chen Liu, Fugen Li, Bin Yi, Xiaoqing Jiang
Journal: Cancer Research (2019)

Abstract Purpose: Biliary tract cancer (BTC) is a devastating disease of the digestive system with poor prognosis. Targeted therapy based on specific genetic alterations has been proven to be an effective treatment for some cancer subtypes. However, the effect of this targeted therapy is unclear in BTC. In this study, we aimed to explore the clinical efficacy and safety of personalized targeted therapy guided by targeted deep sequencing for advanced biliary tract cancer (BTC) patients. Materials and Methods: In this retrospective study, targeted deep sequencing was employed for 49 patients with BTC and the recommendation of biologic agent was offered. Among 32 patients with stage IV and R2 resection, 21 patients underwent conventional chemotherapy (mGEMOX) (chemotherapy group), while the remaining 11 patients received a personalized targeted agent (targeted therapy group). The progression-free survival (PFS), overall survival (OS), disease control rate (DCR) were used to assess the efficacy of treatments, while the grade of treatment-related toxicities was evaluated for safety. Results: The genomic landscape of 49 patients with BTC was depicted by targeted deep sequencing. Further analysis of all alterations demonstrated that these altered genes were highly enriched in the ERBB family or cell cycle pathway. After a median follow-up of 12 months, the targeted therapy group had a significant prolonged PFS (4.5 months vs. 1.5 months, P = 0.014) and a trend of prolonged OS (12.9 months vs. 4.1 months, P = 0.104) in comparison to the chemotherapy group. The DCR in the targeted therapy group was marginally higher but without statistical significance (63.6% vs. 33.3%, P = 0.142). In addition, there was no statistically significant difference in the percentage of patients that experienced Grade &amp;gt;2 treatment-related toxicities in either treatment group (36.4% vs 19.0%, P = 0.397). Conclusions: This real-world clinical study suggests that targeted deep sequencing contributes to guiding personalized targeted therapy based on individual actionable mutations, which may benefit advanced BTC patients. Large umbrella trials of personalized precision therapy are needed to further confirm the clinical efficacy and safety of this therapeutic strategy in BTC. Note: This abstract was not presented at the meeting. Citation Format: Feiling Feng, Qingbao Cheng, Dadong Zhang, Bin Li, Hao Qin, Chang Xu, Miao Han, Yong Yu, Zhizhen Li, Jing-Yu Li, Zhiquan Qiu, Lei Xiong, Chen Liu, Fugen Li, Bin Yi, Xiaoqing Jiang. Targeted deep sequencing contributes to guiding personalized targeted therapy in advanced biliary tract cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 477.
Minor Surgery.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO
Authors: C. Grohe, W. Gleiber, S. Haas, H. Mueller-Huesmann, M. Schulze, J. Atz, R. Kaiser
Journal: Annals of Oncology (2019)

Background: Nintedanib (Vargatef®) is an oral triple angiokinase inhibitor of VEGF-, PDGF- and FGF-receptors approved in the EU and other countries for treatment of locally advanced or metastatic NSCLC of adenocarcinoma histology in combination with docetaxel after 1st line chemotherapy. Data are sparse regarding efficacy and safety of nintedanib in NSCLC pts who had been treated with ICIs. Methods: This interim analysis included 22 pts with locally advanced or metastatic lung adenocarcinoma who received nintedanib and docetaxel in 3rd line following ICIs in 2nd line within the ongoing NIS VARGADO (cohort B). Results: Median age was 58 years (range: 45 – 76), 15/22 pts (68.2%) were men, and 16/22 pts (72.7%) were ECOG PS0/1. 4/22 pts (18.2%) had brain metastases, and 19/22 pts (86.4%) were current or former smokers. 1st line chemotherapy treatments included pemetrexed (15/22 pts, 68.2%), carboplatin (12/22 pts, 54.6%), cisplatin (12/22 pts, 54.6%), bevacizumab (6/22 pts, 27.3%), vinorelbine (4/22 pts, 18.2%), paclitaxel (2/22 pts, 9.1%), and docetaxel (1/22 pts, 4.4%). 2nd line treatments consisted of nivolumab (17/22 pts, 77.3%) or pembrolizumab (5/22 pts, 22.7%). Under nintedanib and docetaxel, 7/12 pts (58.3%) developed a partial response and 3/12 pts (25.0%) showed stable disease; DCR was 83.3% (10/12 pts). Median PFS was 5.5 months (95%CI 1.9 – 8.7). Treatment emergent adverse events (TEAEs) grade ≥3, serious TEAEs, and TEAEs leading to discontinuation were observed in 13/22 pts (59.1%), 11/22 pts (50.0%), and 7/22 pts (31.8%), respectively. Conclusions: Nintedanib, in combination with docetaxel, showed clinically relevant efficacy and an adequate safety profile in stage IIIB/IV lung adenocarcinoma pts following treatment with chemotherapy and ICIs. Further studies are justified to fully explore the potential of nintedanib and docetaxel in this novel setting. Therefore, anti-angiogenesis plus docetaxel may emerge as a subsequent therapeutic principle in patients progressing under ICI therapy. Clinical trial identification: NCT02392455. Legal entity responsible for the study: Boehringer Ingelheim Pharma GmbH & Co. KG. Funding: Boehringer Ingelheim Pharma GmbH & Co. KG. Disclosure: C. Grohe: Research funding/honoraria: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, MSD, Pfizer, Hoffmann-La Roche, Lilly including membership on advisory boards. W. Gleiber: Honoraria for membership on advisory boards: Boehringer Ingelheim. J. Atz, R. Kaiser: Employee: Boehringer Ingelheim Pharma GmbH & Co. KG All other authors have declared no conflicts of interest.
THE HOSPITAL PATHOLOGIST.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A disposable renal biopsy needle
Authors: M. H. Alderman
Journal: JAMA (1968)

<h3>To the Editor:—</h3> With reference to our article, "Initial Clinical Experience With Intraaortic Balloon Pumping in Cardiogenic Shock," which appeared inThe Journal(<b>203</b>:113, 1968), at the time our addendum regarding three additional patients was submitted, a complete follow-up on the sixth patient was not available. The patient subsequently died seven days after the procedure, from pulmonary complications. His hemodynamic status remained stable until his sudden death from pulmonary and renal complications.
ACTION OF COPPER AND ITS SALTS ON ORGANISMS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum 2,3,7,8-tetrachlorodibenzo-p-dioxin levels in US Army Vietnam-era veterans. The Centers for Disease Control Veterans Health Studies
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IMMUNE REACTIONS OF SCARLET FEVER
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Croonian Lectures on the Chemistry and Therapeutics of Uric Acid Gravel and Gout: Delivered before the Royal College of Physicians of London
Authors: W. Roberts
Journal: BMJ (1892)

trousers of the same material.He told us he always made -them himself.They were washed every week; some of them were actually hanging on a line in the room to dry.From Blareau's we went to the house of M. Paniels in the Rue Croix-blanche.Neither the master nor his wife were at home, but a young daughter showed us into a dwelling room, the window of which served to display several sweet stuffs- for a little shop of these things was kept by them.Every- thing was very clean.
AMA Interim Meeting report: Sammons' retirement announced for 1991; AMA board, delegates prepare for a new era
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Word " Os."
Authors: None F.
Journal: JAMA (1897)

San Diego, Cal., Dec. 11, 1897. <h3>To the Editor:</h3> —Were I an editor I should not object perhaps to read the Old English<i>thon</i>, but I should draw the line as do you at the too common substitution of "orem" for the classic and correct accusative of that old neuter noun,<i>os</i>. Truly yours.
Electro-narcosis
Authors: A. S. Paterson
Journal: BMJ (1948)

MIRITISHThen there is a formidable list of unfortunate sequelae, including acute rheumatism, scarlet fever, diphtheria, mastoid disease, pneumonia, haemorrhage, poliomyelitis, neurosis, etc., in which the operation has been the exciting cause and from which recovery may be slow and incomplete.Lastly, there might be mentioned to the anxious parents the risk of local damage of a more or less permanent kind-e.g., distortion of the fauces, loss of uvula, paralysis of palate, etc.By the time these possibilities are explained, the parents' anxiety becomes rrore tolerable and they may even listen to advice about more conservative methods of dealing with tonsil trouble.Mr. Ibbotson's reference to "the utmost, importance that healthy growth should be encouraged and not hindered" raises again the important question, Is there any proof that tonsils and adenoids retard physical growth or mental development any more than similar collections of lymphatic tissue in the armpits or in the groins or in any other part of the body ?-I am, etc., London, N.8.R. P. GARROW.Electro-narcosis SIR,-Your report (May 29, p. 1044) of my lecture at the Royal Society of Medicine on May 11 contains four errors which call for correction.1.The dose of atropine which I recommended was 1/60 gr. (I mg.) and not 1/6 gr.(11 mg.) as stated.2. The statement " . . . it was rare to give an application of less than 200 f/A for the last 30 seconds " should read " for the first 30 seconds."